3-4

CALYX is an US FDA inspected Active Pharmaceutical Ingredient manufacturer with excellent custom synthesis capabilities. Corporate head quarter is located in the commercial hub of India – Mumbai with its manufacturing facilities on the outskirts of Mumbai.

THIS JOB IS EXPIRED !

Theon Pharmaceuticals Ltd.is a pioneering WHO GMP certified pharma company with ultra modern and sophisticated plant situated at NALAGARH in Himachal Pradesh, having strategic tie ups with MNCs. The company has set up a state of the art facility for manufacturing of pharmaceutical formulations viz.Tablets, capsules & dry syrups (β-lactum, cephalosporin’s & general block) with installed capacity of about 1000 million units per annuam.

Tidal was incorporated in the year 1995, with the backbone of a strong professional team with true commitment to healthcare profession.

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc.

Cipla known for its innovative pharmaceutical products backed by latest in technology and creative marketing practices, is enjoying a commanding position among the top pharma companies in the country.
Several specialised therapeutic divisions and promising new products have been launched and many more are in the pipeline.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $3.9 billion in fiscal year 2009 (year ending March 31, 2010).